Professor John Greenman J.Greenman@hull.ac.uk
Professor of Tumour Immunology
Blood test for clinical therapy guidance of non-small cell lung cancer patients
People Involved
A new immunomagnetic microfluidic device for characterizing EGFR mutations in circulating tumor cells from patients withnon-small cell lung cancer (2024)
Journal Article
Ogidi, N. O., Lind, M. J., & Greenman, J. (online). A new immunomagnetic microfluidic device for characterizing EGFR mutations in circulating tumor cells from patients withnon-small cell lung cancer. Tumor Discovery, Article 3987. https://doi.org/10.36922/td.3987ncorporating precision oncology into cancer management has begun to improve clinical outcomes. Accurate sampling techniques that detect molecular aberrations are crucial for effective implementation. Circulating tumor cells (CTCs), derived from prima... Read More about A new immunomagnetic microfluidic device for characterizing EGFR mutations in circulating tumor cells from patients withnon-small cell lung cancer.
LungCARD - Report on worldwide research and clinical practices related to lung cancer (2019)
Journal Article
Jankovic, R., Goncalves, H. J., Cavic, M., Clemente, C., Lind, M., Carrasco, A. M., Nadifi, S., Khyatti, M., Adebambo, T., & Egamberdiev, D. (2019). LungCARD - Report on worldwide research and clinical practices related to lung cancer. Journal of BUON, 24(1), 11-19© 2019 Zerbinis Publications. All Rights Reserved. Purpose: The management of advanced lung cancer has evolved tremendously over the past two decades. Increasing understanding of the molecular changes that drive tumor progression has transformed the... Read More about LungCARD - Report on worldwide research and clinical practices related to lung cancer.